Cerus (NASDAQ:CERS) Stock Price Crosses Above 200-Day Moving Average – Should You Sell?

Cerus Corporation (NASDAQ:CERS)’s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.81 and traded as high as $2.61. Cerus shares last traded at $2.56, with a volume of 2,004,835 shares traded.

Analyst Ratings Changes

Several brokerages have commented on CERS. Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. TD Cowen reiterated a “buy” rating on shares of Cerus in a research report on Monday, January 12th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Cerus currently has an average rating of “Hold”.

Cerus Stock Performance

The business’s fifty day moving average price is $2.30 and its two-hundred day moving average price is $1.81. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.29 and a current ratio of 1.89. The stock has a market capitalization of $491.75 million, a P/E ratio of -32.00 and a beta of 1.52.

Hedge Funds Weigh In On Cerus

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in Cerus by 0.6% during the third quarter. Vanguard Group Inc. now owns 10,783,986 shares of the biotechnology company’s stock worth $17,147,000 after buying an additional 62,663 shares during the period. Wasatch Advisors LP boosted its stake in shares of Cerus by 2.6% during the 2nd quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company’s stock worth $12,033,000 after purchasing an additional 213,917 shares during the period. Millennium Management LLC grew its holdings in Cerus by 17.6% during the 3rd quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company’s stock valued at $5,517,000 after purchasing an additional 519,301 shares during the last quarter. Acadian Asset Management LLC raised its position in Cerus by 38.6% in the 2nd quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company’s stock worth $3,710,000 after purchasing an additional 733,683 shares during the period. Finally, Ieq Capital LLC lifted its stake in Cerus by 1.1% in the fourth quarter. Ieq Capital LLC now owns 2,423,741 shares of the biotechnology company’s stock worth $4,993,000 after purchasing an additional 25,771 shares during the last quarter. Institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.